The NAT1 C1095A polymorphism, maternal multivitamin use and smoking, and the risk of spina bifida.

BACKGROUND The risk of having a child with a neural tube defect (NTD) can be reduced by maternal, periconceptional supplementation with folic acid, but the underlying folate-dependent protective mechanism remains unclear. N-acetyltransferase 1 is involved in acetylation of aromatic and heterocyclic amines and the catabolism of folates. Hence, functional polymorphisms in NAT1, the gene encoding N-acetyltransferase 1, are plausible risk factors for NTDs. Such variants could exert an influence on the risk of NTDs via their role in acetylation or folate catabolism and could act through the maternal or the embryonic genotype. METHODS NAT1 C1095A genotypes and information on maternal, periconceptional multivitamin use and smoking were obtained as part of a family-based study of spina bifida. Associations between spina bifida and the embryonic and maternal NAT1 C1095A genotypes, and potential NAT1 C1095A genotype-exposure interactions were evaluated using log-linear modeling. RESULTS The analyses provided no evidence that the embryonic or maternal NAT1 C1095 genotypes influence the risk of spina bifida independently, or through interactions with maternal use of multivitamins. There was evidence that the embryonic, and possibly the maternal, NAT1 C1095A genotype influence the risk of spina bifida via interactions with maternal smoking status. CONCLUSIONS The genotype for the NAT1 C1095A polymorphism does not appear to be an independent risk factor for spina bifida. However, the results of these analyses provide preliminary evidence that this polymorphism may be associated with the risk of spina bifida in the offspring of women who smoke during early pregnancy.

[1]  G. Shaw,et al.  Periconceptional multivitamin intake during early pregnancy, genetic variation of acetyl-N-transferase 1 (NAT1), and risk for orofacial clefts. , 2004, Birth defects research. Part A, Clinical and molecular teratology.

[2]  G. Shaw,et al.  Maternal Smoking and the Risk of Orofacial Clefts: Susceptibility With NAT1 and NAT2 Polymorphisms , 2004, Epidemiology.

[3]  R. Rozmahel,et al.  Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice. , 2003, Molecular pharmacology.

[4]  D. Hein.  Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. , 2002, Mutation research.

[5]  D. Grant,et al.  Pharmacogenetics of the arylamine N-acetyltransferases: a symposium in honor of Wendell W. Weber. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[6]  C R Weinberg,et al.  The use of case-parent triads to study joint effects of genotype and exposure. , 2000, American journal of human genetics.

[7]  M. Doll,et al.  Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[8]  E. Sim,et al.  A method for genotyping murine arylamine N-acetyltransferase type 2 (NAT2): a gene expressed in preimplantation embryonic stem cells encoding an enzyme acetylating the folate catabolite p-aminobenzoylglutamate. , 1999, Biochemical pharmacology.

[9]  C R Weinberg,et al.  Allowing for missing parents in genetic studies of case-parent triads. , 1999, American journal of human genetics.

[10]  B. Futscher,et al.  Developmental expression of N-acetyltransferases in C57BI/6 mice. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[11]  V. Perry,et al.  Immunochemical detection of arylamine N-acetyltransferase during mouse embryonic development and in adult mouse brain. , 1998, Teratology.

[12]  C R Weinberg,et al.  A log-linear approach to case-parent-triad data: assessing effects of disease genes that act either directly or through maternal effects and that may be subject to parental imprinting. , 1998, American journal of human genetics.

[13]  D. Bell,et al.  Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. , 1995, Cancer research.

[14]  E. Sim,et al.  Purification of recombinant human N-acetyltransferase type 1 (NAT1) expressed in E. coli and characterization of its potential role in folate metabolism. , 1995, Biochemical pharmacology.

[15]  R. Minchin.  Acetylation of p-aminobenzoylglutamate, a folic acid catabolite, by recombinant human arylamine N-acetyltransferase and U937 cells. , 1995, The Biochemical journal.

[16]  A. Czeizel,et al.  Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. , 1992, The New England journal of medicine.